Corindus Vascular Robotics (CVRS) POS AM 21 Apr 15 Prospectus update (post-effective amendment) Financial data

Document_and_Entity_Informatio

Document and Entity Information	12 Months Ended
	Dec. 31, 2014
Document And Entity Information [Abstract]
Document Type	POS AM
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Trading Symbol	CVRS
Entity Registrant Name	Corindus Vascular Robotics, Inc.
Entity Central Index Key	1528557
Entity Filer Category	Smaller Reporting Company

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:
Cash and cash equivalents	$28,526	$9,845
Accounts receivable, net of allowance for doubtful accounts of $3 and $0, respectively	473	35
Due from related party	0	125
Inventories, net	1,519	2,464
Prepaid expenses and other current assets	574	494
Total current assets	31,092	12,963
Property and equipment, net	1,284	1,437
Deposits and other assets	222	223
Deferred inventory costs	102
Notes receivable due from stockholders	136	145
Total assets	32,836	14,768
Current Liabilities:
Accounts payable	2,005	315
Accrued expenses	1,137	1,261
Deferred revenue	202
Current portion of long-term debt	1,517
Total current liabilities	4,861	1,576
Long-term liabilities:
Deferred revenue, net of current portion	531
Other liabilities	68
Long-term debt, net of current portion	7,594
Warrant liability		3,152
Total long-term liabilities	8,193	3,152
Total liabilities	13,054	4,728
Commitments and Contingencies (Note 13)
Stockholders' equity:
Preferred stock, par value $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value; 250,000,000 shares authorized; 73,360,287 shares and 105,883,157 shares issued and outstanding, respectively	11	7
Additional paid-in capital	104,648	70,369
Accumulated deficit	-84,877	-60,336
Total stockholders' equity	19,782	10,040
Total liabilities and stockholders' equity	$32,836	$14,768

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$0	$3
Preferred stock, par value	$0.00	$0.00
Preferred stock, authorized shares	10,000,000	10,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, par value	$0.00	$0.00
Common stock, authorized shares	250,000,000	250,000,000
Common stock, issued shares	105,883,157	73,360,287
Common stock, outstanding shares	105,883,157	73,360,287

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Revenue	$2,983	$896
Cost of revenue	4,904	2,430
Gross loss	-1,921	-1,534
Operating expenses:
Research and development	6,607	4,793
Selling, general and administrative	13,002	8,221
Restructuring charge	175
Total operating expenses	19,784	13,014
Operating loss	-21,705	-14,548
Other income (expense):
Warrant revaluation	-2,421	-171
Interest and other income (expense)	-415	28
Total other expense, net	-2,836	-143
Net loss and comprehensive loss	($24,541)	($14,691)
Net loss per share-basic and diluted	($0.29)	($0.20)
Weighted-average common shares used in computing net loss per share-basic and diluted	84,990,198	73,360,259

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Total	Common Stock $0.0001 Par Value [Member]	Additional Paid in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Beginning balance at Dec. 31, 2012	$24,412	$7	$70,050	($45,645)
Beginning balance, shares at Dec. 31, 2012		73,360,162
Exercise of options for common stock	0	0	0	0
Exercise of options for common stock, shares		125
Issuance costs related to common stock	-10		-10
Stock-based compensation expense	329		329
Net loss	-14,691			-14,691
Ending balance at Dec. 31, 2013	10,040	7	70,369	-60,336
Ending balance, shares at Dec. 31, 2013		73,360,287
Issuance costs related to common stock	-1,179
Stock-based compensation expense	377		377
Reclassification of warrant liability	5,803		5,803
Issuance of common stock in connection with reverse acquisition, Value	-3	2	-5
Issuance of common stock in connection with reverse acquisition, shares		20,856,300
Issuance of common stock to private investor	2,000		2,000
Issuance of common stock to private investor, shares		1,000,000
Issuance of common stock in connection with private placement of common stock, net of offering costs	25,487	2	25,485
Issuance of common stock in connection with private placement of common stock, net of offering costs, shares		10,666,570
Issuance of warrants to purchase common stock to lender	619		619
Net loss	-24,541			-24,541
Ending balance at Dec. 31, 2014	$19,782	$11	$104,648	($84,877)
Ending balance, shares at Dec. 31, 2014		105,883,157

Consolidated_Statement_of_Stoc1

Consolidated Statement of Stockholders' Equity (Parenthetical) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Statement of Stockholders' Equity [Abstract]
Common stock offering cost	$1,179	$10
Common stock, par value	$0.00	$0.00

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net loss and comprehensive loss	($24,541)	($14,691)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	622	607
Stock-based compensation expense	377	329
Write down of inventories	341
Accretion of interest expense	106
Warrant revaluation.	2,421	171
Changes in operating assets and liabilities:
Accounts receivable	-438	-23
Due from related party	125	130
Prepaid expenses and other current assets	-80	134
Deferred inventory costs	-102
Inventories	257	-2,313
Deposits and other assets	24	89
Accounts payable	1,640	-151
Accrued expenses and other liabilities	-56	480
Deferred revenue	733	-65
Net cash used in operating activities	-18,571	-15,303
Investing activities
Purchase of property and equipment	-122	-378
Net cash used in investing activities	-122	-378
Financing activities
Proceeds from the issuance of common stock, net	27,487	-10
Proceeds from issuance of long-term debt and warrants, net of deferred financing costs and discounts of $160	9,890
Other	-3
Net cash provided by (used in) financing activities	37,374	-10
Net increase (decrease) in cash and cash equivalents	18,681	-15,691
Cash and cash equivalents at beginning of period	9,845	25,536
Cash and cash equivalents at end of period	28,526	9,845
Supplemental Disclosure of Cash Flow Information:
Transfer from inventories to property and equipment in the field	347	588
Reclassification of warrant liability to stockholders' equity	5,803
Financing costs included in accounts payable	50
Interest paid	$266

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Statement of Cash Flows [Abstract]
Deferred financing costs and discounts	$160

Nature_of_Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Nature of Operations	1	Nature of Operations
	The Company
	Corindus Vascular Robotics, Inc. (the “Company”), a Nevada corporation (formerly named Your Internet Defender, Inc. (“YIDI”), acquired Corindus, Inc., a privately-held company, in a reverse acquisition on August 12, 2014. The Company’s corporate headquarters and research and development facility are in Waltham, Massachusetts and the Company is engaged in the marketing, sales and development of robotic-assisted catheterization systems (“CorPath System”).
	Since its inception on March 21, 2002, the Company has devoted its efforts principally to research and development, business development activities, and raising capital. In July 2012, the Company received clearance from the United States Food and Drug Administration to market its CorPath System in the United States and shipped its first commercial product under this clearance in September 2012. In 2013, the Company moved into the growth stage, investing in sales and marketing in order to build its customer base. The Company’s future capital requirements will depend upon many factors, including progress with developing, manufacturing and marketing its technologies, the time and costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims and other proprietary rights, its ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including regulatory changes affecting medical procedure reimbursement, and overall economic conditions in the Company’s target markets.
	Reverse Acquisition Transaction
	On August 12, 2014, the Company, as the legal acquirer, consummated a reverse acquisition of Corindus, Inc., the accounting acquirer (the “Acquisition”) pursuant to the Securities Exchange and Acquisition Agreement (the “Acquisition Agreement”), entered into between the Company and Corindus, Inc. Prior to the Acquisition, all outstanding shares of Series A through E Redeemable Convertible Preferred Stock of Corindus, Inc. were converted into 2,811,499 shares of Common Stock of Corindus, Inc.
	Pursuant to the terms of the Acquisition Agreement (i) all outstanding shares of common stock of Corindus, Inc., $0.01 par value per share, were exchanged for shares of Company Common Stock, $0.0001 par value per share, and (ii) all outstanding options and warrants to purchase shares of Common Stock of Corindus, Inc. were exchanged for or replaced with options and warrants to acquire shares of Common Stock of the Company. The exchange ratio was one for 25.00207 shares.
	All share and per share amounts in the consolidated financial statements and related notes have been retrospectively adjusted to reflect (i) the conversion of the Series A through E Redeemable Convertible Preferred Stock into common stock and (ii) the one for 25.00207 exchange of shares of Common Stock.
	At the closing of the Acquisition, the Company transferred the former business of YIDI to a former officer, director and shareholder of YIDI, in exchange for the satisfaction of a promissory note issued to the former officer, director and shareholder in the principal amount of approximately $249 and the assumption of liabilities related to the former operations.
	Immediately after the transfer of the former business of YIDI, the business of Corindus, Inc. became the sole focus of the combined company and the combined company’s name was changed to Corindus Vascular Robotics, Inc.
	2014 Financings
	In connection with the Acquisition, the Company issued 1,000,000 shares of Common Stock to a private investor at a price of $2.00 per share in exchange for proceeds of $2,000. See Note 3 for further discussion of this transaction.
	On September 12, 2014, the Company entered into a Securities Purchase Agreement with multiple investors relating to the issuance and sale of the Company’s common stock in a private placement, which closed on September 16, 2014. The Company sold 10,666,570 shares of common stock at $2.50 per share, for an aggregate purchase price of approximately $26,666 with net proceeds to the Company of $25,487.
	Liquidity
	The Company has incurred losses since inception and has funded its operations primarily through the issuance of capital stock and debt. As of December 31, 2014, the Company had an accumulated deficit of $84,877, and net borrowings outstanding of $9,111, of which $2,000 is contractually due in 2015.
	The Company has cash resources of $28,526 and working capital of $26,231. The Company believes that these cash resources will be sufficient to meet the Company’s cash requirements through the end of 2015, including funding its anticipated losses and scheduled debt maturities. Additionally, the Company is in compliance with its debt covenant requirements as of December 31, 2014 and expects to remain in compliance throughout 2015. As the Company continues to incur losses, transition to profitability is dependent upon achieving a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until doing so, intends to fund future operations through additional debt or equity offerings. There can be no assurances, however, that additional funding will be available on terms acceptable to the Company, if at all.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies	2	Significant Accounting Policies
	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Corindus, Inc. and Corindus Security Corporation, which was created on December 21, 2012 to hold and invest the proceeds from issuance of equity. All intercompany transactions and balances have been eliminated in consolidation. The functional currency of both wholly-owned subsidiaries is the U.S. dollar and, therefore, the Company has not recorded any currency translation adjustments.
	Reclassification
	Sales and marketing expenses of $5,676 in 2013 have been reclassified to selling, general and administrative expenses to conform to 2014 presentation.
	Segment Information
	The Company operates in one business segment, which is the marketing, sales and development of robotic-assisted vascular interventions. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the chief operating decision maker has made such decisions and assessed performance at the company level, as one segment. The Company’s chief operating decision maker is the Chief Executive Officer.
	Revenues from domestic customers amounted to $896 in 2013 and approximately $2,200 in 2014. Revenues from international customers, primarily in Dubai and Israel, amounted to none in 2013 and approximately $1,000 in 2014.
	Use of Estimates
	The process of preparing financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements. Such management estimates include those relating to revenue recognition, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards and warrants, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.
	Financial Instruments
	Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:
	Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.
	Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.
	There were no assets and liabilities as of December 31, 2014 that are measured and recorded in the financial statements at fair value on a recurring basis. There were no transfers between Level 1, 2 or 3 assets or liabilities during the years ended December 31, 2013 or 2014. The following table shows the Company’s assets and liabilities as of December 31, 2013 that are measured and recorded in the financial statements at fair value on a recurring basis:
			December 31, 2013
			Quoted Prices in			Significant			Unobservable
			Active Markets for			Other			Inputs
			Identical			Observable Inputs
			Assets or Liabilities
			Level 1			Level 2			Level 3
	Assets
	Money market funds (a)		$	9,700		$	—		$	—
	Liabilities
	Warrant liability (b)		$	—		$	—		$	3,152
	(a)	The fair values of the Company’s money market funds, which are included in cash and cash equivalents, are based on quotes received from third-party banks.
	(b)	See Note 12 for a roll-forward of the warrant liability and a discussion of the valuation of this financial instrument.
	The Company’s financial instruments of deposits and notes receivable are carried at cost and approximate their fair values given the liquid nature of such items. The fair value of the Company’s long-term debt amounted to $8,748 at December 31, 2014, which was based on a discounted cash flow analysis, which included level 3 inputs.
	Cash Equivalents
	The Company considers highly liquid short-term investments, which consist of money market funds, with original maturity dates of three months or less at the date of purchase to be cash equivalents. From time to time, the Company’s cash balances may exceed federal deposit insurance limits.
	Product Warranty and Allowance for Doubtful Accounts
	The Company’s allowance for doubtful accounts was $3 and none at December 31, 2013 and 2014, respectively. The Company’s accounts receivable consist primarily of amounts due from large, well-capitalized customers and while the Company reviews their creditworthiness, collectability is generally not an issue. The Company records an allowance for doubtful accounts, when necessary, based on the potential for minor collectability issues within the customer base. The amounts have not been material to date.
	Customers are permitted to return defective products under the Company’s standard product warranty program. For CorPath Systems, the Company’s standard one-year warranty provides for the repair of any product that malfunctions. Return and replacement can only occur if a material breach of the warranty remains uncured for 30 days. A roll-forward of the Company’s warranty liability is as follows:
	Balance at December 31, 2012		$	19
	Provision for warranty obligations			57
	Settlements			(47	)
	Balance at December 31, 2013			29
	Provisions for warranty obligations			96
	Settlements			(64	)
	Balance at December 31, 2014		$	61
	Inventories
	Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. The Company routinely monitors the recoverability of its inventory and records the lower of cost or market reserves based on current selling prices and reserves for excess and obsolete inventory based on historical and forecasted usage, as required. Scrap and excess manufacturing costs are charged to cost of revenue as incurred and not capitalized as part of inventories.
	Property and Equipment
	Property and equipment is carried at cost. Major items and betterments are capitalized; maintenance and repairs are charged to expense as incurred. The Company capitalizes certain costs incurred in connection with developing or obtaining internal-use software. Software costs that do not meet capitalization criteria are expensed as incurred. Demonstration equipment represents internally manufactured capital equipment that is used on-site at trade shows and at customer locations to demonstrate the CorPath System. Field equipment represents internally manufactured capital equipment placed at customer locations under a program that involves the placement of a system at the customer’s site and the customer’s agreement to purchase a minimum number of cassettes each month. At December 31, 2014, the Company had placed five field equipment units and one unit for a customer’s evaluation under such arrangements.
	Depreciation on the demonstration equipment is charged to selling, general and administrative and the deprecation on the field equipment is charged to cost of revenue. Depreciation is computed under the straight-line method over the estimated useful lives of the respective assets.
	Depreciation is provided over the following estimated asset lives:
	Machinery and equipment		5 years
	Computer equipment		3 years
	Office furniture and equipment		5 years
	Leasehold improvements		Shorter of life of lease or useful life
	Vendor tooling		3 years
	Software		4 years
	Demonstration equipment		3 years
	Field equipment		3 years
	Impairment of Long-Lived Assets
	The Company’s long-lived assets principally consist of property and equipment. The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. An impairment loss is recognized when expected cash flows are less than an asset’s carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating performance and estimated future undiscounted cash flows of the underlying assets. The Company’s policy is to record an impairment loss when it is determined that the carrying amount of the asset may not be recoverable. No such impairment charges have been recognized.
	Revenue Recognition
	The CorPath System is a capital medical device used by hospitals and surgical centers to perform heart catheterizations. Use of the CorPath System requires a sterile, single-use cassette (the “CorPath Cassette”), which are sold separately, for each procedure. Products are sold to customers with no rights of return. The Company recognizes revenue on the sale of products when the following criteria are met:
		•		Persuasive evidence of an arrangement exists
		•		The price to the buyer is fixed or determinable
		•		Collectability is reasonably assured
		•		Risk of loss transfers and the product is delivered.
	In each arrangement, the Company is responsible for installation of the CorPath System and initial user training, which services are deemed essential to the functionality of the system. Therefore, the Company recognizes system revenue when the CorPath System is delivered and installed, and accepted by the end user customer.
Each CorPath System is sold with a standard one year warranty, which provides that the CorPath System will function as intended and during that one year period, the Company will either replace the product or a portion thereof or provide the necessary repair service during the Company’s normal service hours. The Company accrues for the estimated costs of the warranty once the CorPath System revenue is recognized.
The Company generally enters into multiple element arrangements, which include the sale of a CorPath System with an initial order of CorPath Cassettes, and may include either a basic service plan or a premium service plan. The basic service plan provides for an extended warranty period and the premium service plan provides for the extended warranty as well as component upgrades. Deliverables, which are accounted for as separate units of accounting under multiple-element arrangements include: (a) the CorPath System, including delivery installation and initial training, which are subject to customer acceptance and (b) the initial shipment of CorPath Cassettes to the customer, and may include either (c) a basic service plan or (d) a premium service plan.
The Company recognizes revenue on multiple-element arrangements in accordance with Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements, based on the estimated selling price of each element. In accordance with ASU 2009-13, the Company uses vendor-specific objective evidence (“VSOE”), if available, to determine the selling price of each element. If VSOE is not available, the Company uses third-party evidence (“TPE”) to determine the selling price. If TPE is not available, the Company uses its best estimate to develop the estimated selling price (“BESP”). The Company uses BESP to determine the selling price of its systems as well as the basic and premium service plans. BESP is determined based on estimated costs plus a reasonable margin, and has generally been consistent with the price charged to the customer for such products and services. The determination of BESP also considers the price of the service plans charged to customers when such services are sold separately in subsequent transactions. The Company also uses BESP to determine the selling price of the initial order of cassettes, which considers the price at which it charges its customers when the cassettes are sold separately.
Revenue related to basic service plans is recognized on a straight-line basis over the life of the service contract. Revenue related to premium service plans is recognized over the life of the service contract, with consideration given to the expected timing of costs to be incurred related to the delivery of component upgrades. Revenues from accessories are recorded upon delivery and services provided by the Company outside of a basic or premium service contract are recognized as the services are provided.
There are no performance, cancellation, termination, and refund-type provisions under the Company’s multiple element arrangements.
On January 21, 2011, the Company entered into a distributor agreement with Philips Medical Systems Nederland, B.V. (“Philips”) appointing Philips to be the sole worldwide distributor for the promotion and sale of the Company’s CorPath System. Under the agreement, Philips sold the equipment directly to the end user and the Company was responsible for installation and initial training. Revenue was recognized on a net basis based on the amount billed to Philips and upon acceptance of the system by the end-user customer. At December 31, 2013, Philips owed the Company $125, for systems shipped under the distribution agreement. At December 31, 2014, there were no amounts outstanding from Philips. This agreement with Philips expired on August 7, 2014.
The Company also sells CorPath Cassettes under a CorPath Utilization Program (“CUP”), which is a multi-year arrangement that involves the placement of a CorPath System at a customer’s site free of charge and the customer agrees to purchase a minimum number of CorPath Cassettes each month at a premium over the regular price. The Company records revenue upon shipment of the cassettes based on the selling price of the CorPath Cassettes. The system is capitalized as field equipment in property and equipment and is depreciated on a straight line basis through cost of revenue over the estimated useful life of the system, which generally approximates the length of the CUP program contract, which is typically 36 months. Revenues under this program have not been significant to date.
The Company also uses a One-Stent program to demonstrate its confidence in the CorPath System’s ability to help accurately measure anatomy and precisely place only one stent per lesion. The Company provides eligible customers registered under the program a $1 credit against future CorPath Cassette purchases for a qualifying CorPath percutaneous coronary intervention (“PCI”) procedure which uses more than one stent per lesion. The estimated cost of honoring the potential obligation under the stent program is recorded as a reduction of revenue at the time of shipment. These costs have not been significant to date.
The Company records shipping and handling costs as a selling expense in the period incurred, and records payments from customers for shipping costs as a reduction of selling expenses. Such amounts have not been material in the periods presented. The Company recorded medical device excise tax in the amount of $29 in 2013 and $40 in 2014, which is included in selling, general and administrative expenses.
Research and Development
Costs for research and development are expensed as incurred. Research and development expense consists primarily of salaries, salary-related expenses and costs of contractors and materials.
Income Taxes
The Company accounts for income taxes using the liability method, whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.
The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates these tax positions on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
The Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.
Stock-Based Compensation
The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock award. The Company recognizes compensation costs resulting from the issuance of stock-based awards to non-employees as an expense in the consolidated statements of operations over the service period based on a measurement of fair value for each stock award at each performance date and period end.
Prior to the completion of the reverse acquisition, the fair value of the common stock was determined by the Board of Directors after considering a broad range of factors, including the results obtained from an independent third-party valuation, the illiquid nature of an investment in the Company’s Common Stock, the Company’s historical financial performance and financial position, the Company’s future prospects and opportunity for liquidity events, and recent sale and offer prices of Common and Preferred Stock in private transactions negotiated at arm’s length. Subsequent to the completion of the reverse acquisition, the fair value of the Common Stock was obtained from quoted market prices on the OTCQB as provided by OTC Market Groups, Inc.
The following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes-Merton option-pricing model (“Black Scholes Model”):
		Years Ended December 31,
		2013			2014
Risk-free interest rate			0.72% to 1.43	%		1.89% to 2.01	%
Expected term in years			5.75 to 6.25			6.25
Expected volatility			80	%		50	%
Expected dividend yield			0	%		0	%
The risk-free interest rate assumption is based upon observed U.S. government security interest rates with a term that is consistent with the expected term of the Company’s employee stock options. The expected term is based on the average of the vesting period and contractual term of the Company’s options given the lack of historical data available. The Company does not pay a dividend, and is not expected to pay a dividend in the foreseeable future.
Due to a lack of a public market for the Company’s Common Stock for an extended period of time, the Company utilized comparable public companies’ volatility rates as a proxy of its expected volatility for purposes of the Black-Scholes Model. Stock-based compensation expense is recorded net of estimated forfeitures and is adjusted periodically for actual forfeitures. The Company uses historical data to estimate forfeiture rates. For the year-ended December 31, 2013 and 2014, forfeitures were estimated to be 4.9% and 6.0%, respectively.
Warrant Liability
The Company reviews the terms of warrants issued in connection with the applicable accounting guidance and classifies warrants as a long-term liability on the consolidated balance sheets if the warrant may conditionally obligate the Company to transfer assets, including repurchase of the Company’s capital stock, at some point in the future. Warrants to purchase shares of redeemable convertible preferred stock met these criteria and therefore required liability-classification. The Company classifies warrants within stockholders’ equity on the consolidated balance sheets if the warrants are considered to be indexed to the Company’s own capital stock, and otherwise would be recorded in stockholders’ equity.
Liability-classified warrants are subject to re-measurement at each balance sheet date, and any change in fair value is recognized as a component of other income (expense) in the consolidated statements of operations. The Company estimates the fair value of these warrants at issuance and each balance sheet date thereafter using the Black-Scholes Model as described in the stock-based compensation section above, based on the estimated market value of the underlying Redeemable Convertible Preferred Stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying redeemable convertible preferred stock. The fair value of the Redeemable Convertible Preferred Stock was determined by the Board of Directors after considering a broad range of factors, including the results obtained from an independent third-party valuation, the illiquid nature of an investment in the Company’s Redeemable Convertible Preferred Stock, the Company’s historical financial performance and financial position, the Company’s future prospects and opportunity for liquidity events, and recent sale and offer prices of Common and Preferred Stock in private transactions negotiated at arm’s length.
The Company had warrants outstanding to purchase shares of Series A, D and E Redeemable Convertible Preferred Stock, which converted into warrants to purchase shares of Common Stock at the date of the Acquisition. Prior to the Acquisition, the warrant instruments required mark-to-market accounting which was recorded in the statements of operations based on their fair values determined using the Black-Scholes Model and the fair value of underlying Preferred Stock. The warrant instruments were re-valued for the last time at the date of the Acquisition and reclassified into stockholders’ equity in 2014.
Concentrations of Credit Risk and Significant Customers
The Company had one customer, Philips, who accounted for approximately 71% and 11% of its revenues in 2013 and 2014, respectively. Philips also accounted for approximately 78% and 0% of its accounts receivables at December 31, 2013 and 2014, respectively. The Company had no other customers that accounted for greater than 10% of its revenues or greater than 10% of its accounts receivable as of December 31, 2013.
The Company had the following other customers that accounted for greater than 10% of its revenues in 2014:
Customer		Percent of Revenues
A			27	%
B			11	%
C			12	%
D			10	%
Additionally, Customer C accounted for 27% of the Company’s accounts receivable balance at December 31, 2014. The Company also had one other customer that accounted for 25% of its accounts receivable balance at December 31, 2014, but did not exceed 10% of its revenues in 2014.
The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.
Related-Party Transactions
On January 21, 2011, the Company entered into a distributor agreement with Philips appointing Philips to be the sole distributor for the promotion and sale of the Company’s CorPath System. The agreement was terminated on August 7, 2014. The Company continues to sell CorPath Systems through Philips on a sale by sale basis under a non-exclusive arrangement under mutually agreeable terms, which may include a continued level of discounted pricing, until such time the Company either executes a new distribution arrangement with Philips or the Company no longer does business with Philips.
For the years ended December 31, 2013 and 2014, the Company recorded revenues of $630 and $315, respectively, from shipments to Philips under the distribution agreement. At December 31, 2013 and 2014, Philips owed the Company $125 and $0, respectively, resulting from selling activity under the agreement.
In the fourth quarter of 2014, the Company participated in the formation of a not-for-profit, which was established to generate awareness of the health risks linked to the use of fluoroscopy in hospital catheterization. The Company’s Chief Executive Office and one of its senior executives represent two of the three voting members of the board of directors of the entity. As a result, under the voting model used for the consolidation of related parties, which are controlled by a company, the Company has consolidated the financial statements of the entity, which have no assets or liabilities on its balance sheet at December 31, 2014 and expenses of approximately $18.
Recent Accounting Pronouncements Not Yet Adopted
In May 2014, the FASB issued ASU No. 2014-09 – Revenue from Contracts with Customers (Topic 606). ASU 2014-09 supersedes most of the existing guidance on revenue recognition in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In applying the revenue model to contracts within its scope, an entity will need to (i) identify the contract(s) with a customer (ii) identify the performance obligations in the contract (iii) determine the transaction price (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 is effective for public entities for annual and interim periods beginning after December 15, 2016. The ASU allows for either full retrospective adoption, where the standard is applied to all of the periods presented, or modified retrospective adoption, where the standard is applied only to the most current period presented in the financial statements. The Company is currently assessing the impact of this standard to its consolidated financial statements.
In January 2015, the FASB issued Financial Accounting Standards Update - Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Subtopic 225-20, Income Statement—Extraordinary and Unusual Items, previously required that an entity separately classify, present, and disclose extraordinary events and transactions. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 and may be applied prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently assessing the impact of this standard to its consolidated financial statements.

Reverse_Acquisition

Reverse Acquisition	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Reverse Acquisition	3	Reverse Acquisition
	On August 12, 2014, Corindus, Inc., as the accounting acquirer, acquired the operations of the YIDI business and then immediately transferred YIDI’s operations to a former officer, director and shareholder of YIDI in exchange for the satisfaction of a promissory note issued to YIDI’s former officer, director and shareholder in the principal amount of approximately $249 and the assumption of liabilities related to the former operations.
	All share and per share amounts in the consolidated financial statements and related notes have been retrospectively adjusted to reflect (i) the conversion of the Series A through E Redeemable Convertible Preferred Stock into common stock and (ii) the one for 25.00207 exchange of shares of Common Stock. Additionally, the Company’s warrant liability was reclassified into stockholders’ equity on the date of the Acquisition since the warrants no longer met the definition of a liability. The exchange of options to purchase Common Stock of the Company for options to purchase Common Stock of YIDI resulted in a modification of the awards; however, this impact of such modification was not material.
	Pursuant to the terms of the Acquisition Agreement (i) all outstanding shares of common stock of Corindus, Inc., $0.01 par value per share, were exchanged for 94,216,587 shares of the Company common stock, $0.0001 par value per share, and (ii) all outstanding options and warrants to purchase shares of common stock of Corindus, Inc. were exchanged for or replaced with options and warrants to acquire shares of common stock of the Company. The exchange ratio used was one for 25.00207 shares.
	YIDI was the legal acquirer of Corindus, Inc. in this transaction. However, since former Corindus, Inc. shareholders owned, immediately following the Acquisition, 80% of the combined company on a fully diluted basis and all members of the combined company’s executive management and Board of Directors, were from Corindus, Inc., Corindus Inc. was deemed to be the acquiring company for accounting purposes and the transaction was accounted for as a reverse acquisition in accordance with U.S. GAAP.
	Prior to the divestiture of YIDI’s former business, the Company performed an allocation of the purchase price for YIDI based on estimated fair value of the acquired assets and liabilities prior to the disposition of the remaining business of YIDI:
	Purchase price-assumption of note payable to former officer		$	249
	Allocation of purchase price:
	Intangible assets acquired		$	262
	Accrued expenses assumed			(13	)
	Net assets acquired		$	249
	The Company incurred costs of approximately $1,100 related to the Acquisition for the year ended December 31, 2014, which are included in selling, general and administrative expenses.
	The subsequent spin-off of the former business resulted in no gain or loss on the disposal of a business as it was sold for its net assets, which represented fair value.
	The results of operations for YIDI were immaterial for the years ended December 31, 2013 and 2014 and as such no pro forma statement of operations data is presented.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventories	4	Inventories
	The Company’s inventories consist of the following:
			December 31,
			2013		2014
	Raw materials		$	634	$	861
	Work in progress			—		198
	Finished goods			1,830		460
			$	2,464	$	1,519
	The Company wrote down inventories by $341 in 2014 to properly reflect inventories at the lower of cost or market.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property and Equipment	5	Property and Equipment
	Property and equipment are stated at cost and are being depreciated using the straight-line basis over the assets’ estimated useful lives. Depreciation expense was $607 and $622 for the fiscal years 2013 and 2014, respectively. Property and equipment consist of the following:
			December 31,
			2013			2014
	Machinery and equipment		$	298		$	334
	Computer equipment			273			273
	Office furniture and equipment			353			355
	Leasehold improvements			63			67
	Vendor tooling			671			711
	Software			450			490
	Demonstration equipment			669			633
	Field equipment			205			588
				2,982			3,451
	Less accumulated depreciation and amortization			(1,545	)		(2,167	)
	Property and equipment, net		$	1,437		$	1,284

Notes_Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Notes Receivable	6	Notes Receivable
	On June 14, 2010, the Company loaned funds to certain stockholders of the Company for tax payments to be made to the Israel Tax Authority in connection with a tax ruling related to a reorganization that took place in 2008 and the Company received non-interest bearing notes receivable, which documented such loans. Total amount of notes receivable issued was $145.
	The notes receivable are repayable upon the disposition of the Company’s Common Stock. Notes receivable in the amount of $145 and $136 were outstanding at December 31, 2013 and 2014, respectively. The Company assessed the notes receivable for impairment and concluded that there was no impairment indicators at December 31, 2013 and 2014. The Company does not believe there is any significant collection risk associated with the notes receivable at December 31, 2013 and 2014.

Accrued_Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accrued Expenses	7	Accrued Expenses
	Accrued expenses consist of the following:
			December 31,
			2013		2014
	Payroll and benefits		$	493	$	185
	Professional and consultant fees			242		496
	Product development costs			117		62
	Commissions			107		85
	Warranty			29		61
	Other			273		248
			$	1,261	$	1,137

LongTerm_Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Long-Term Debt	8	Long-Term Debt
	On June 11, 2014, the Company entered into a Loan and Security Agreement pursuant to which the lender agreed to make available to the Company $10,000 in two separate $5,000 loans under secured promissory notes. The initial note was made on June 11, 2014 in an aggregate principal amount equal to $5,000 (the “Initial Promissory Note”) and is repayable in equal monthly installments of principal and interest over 27 months beginning on July 1, 2015. Prior to July 1, 2015, the Company is required to make interest only payments. The Initial Promissory Note bears interest at a rate equal to the greater of (a) 11.25% or (b) 11.25% plus the Wall Street Journal Prime Rate, less 3.25%, and includes an additional interest payment of $125,000 due no later than October 1, 2017, which is accreted over the term of the loan.
	On December 31, 2014, the Company borrowed the additional $5,000 (the “Second Promissory Note”) under the Loan and Security Agreement. The Second Promissory note is also repayable in equal monthly installments of principal and interest over 27 months beginning on July 1, 2015. Prior to July 1, 2015, the Company is required to make interest only payments. The Second Promissory Note bears interest at a rate equal to the greater of (a) 9.95% or (b) 9.95% plus the Wall Street Journal Prime Rate, less 3.25%, and also includes an additional interest payment of $125,000 due no later than October 1, 2017, which is accreted over the term of the loan. The notes are secured by substantially all the assets of the Company.
	In connection with the Initial Promissory Note, the Company issued the lender warrants to purchase 177,514 shares of the Company’s Common Stock at an exercise price of $1.41 per share. The fair value of the warrant issued to the lender was determined to be $230 at the date of issuance, and was recorded as a discount on the debt. Additionally, in connection with the Second Promissory Note, the Company issued the lender warrants to purchase 177,514 shares of the Company’s Common Stock at an exercise price of $1.41 per share. The fair value of the warrant issued to the lender was determined to be $619 at the date of issuance, and was recorded as a discount on the debt. The Company amortizes the debt discount to interest expense over the term of the debt using the effective interest method.
	The Company estimated the fair value of these warrants using the Black-Scholes Model based on the estimated market value of the underlying Common Stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying common stock. The Company used the following assumptions for the valuation of its warrants issued on the following dates:
			June 11, 2014			December 31, 2014
	Risk-free interest rate			2.5	%		2.17	%
	Dividend yield			0	%		0	%
	Expected volatility			50	%		50	%
	Expected term (years)			10			9.44
	The Loan and Security Agreement also contains covenants which include certain restrictions with respect to subsequent indebtedness, liens, loans and investments, asset sales and share repurchases and other restricted payments, subject to certain exceptions. The Loan and Security Agreement also contains financial reporting obligations. An event of default under the Loan and Security Agreement includes, but is not limited to, breach of covenants, insolvency, and occurrence of any default under any agreement or obligation of the Company.
	Borrowings outstanding, net of unamortized discount of $889, amounted to $9,111 at December 31, 2014. Future principal payments under the borrowing arrangement as of December 31, 2014 are as follows:
	Year ending December 31:
	2015		$	2,022
	2016			4,378
	2017			3,600
			$	10,000

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Taxes	9	Income Taxes
	There was no federal or state provision for income taxes for the years ended December 31, 2013 or 2014 due to the Company’s operating losses and a full valuation allowance on deferred income tax assets for all periods since inception. All of the Company’s loss before provision for income taxes is attributable to its United States operations.
	The Company’s effective income tax rate differs from the statutory federal income tax rate as follows:
			Years Ended December 31,
			2013			2014
	Statutory U.S. federal rate			34	%		34	%
	State income tax			4.7			1.7
	Permanent items			0.6			(3.8	)
	Change in taxing status in Massachusetts to a manufacturer			—			(4.9	)
	Other			(0.8	)		(0.7	)
	Federal R&D credits			2			1.2
	State R&D and other credits			0.5			0.7
	Change in valuation allowance			(41.0	)		(28.2	)
	Total expense (benefit)			—	%		—	%
	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and the related valuation allowance were as follows, in thousands:
			December 31,
			2013			2014
	Deferred income tax assets:
	Operating loss carryforwards		$	12,299		$	20,178
	Start-up expenditures			3,316			2,807
	Property and equipment			99			46
	Intangible assets			3,059			2,589
	Stock-based compensation expense			666			738
	Research and development credit carryforwards			878			1,216
	Accrued expenses and other			652			307
	Total deferred income tax assets			20,969			27,881
	Valuation allowance			(20,969	)		(27,881	)
	Net deferred income tax assets		$	—		$	—
	The Company has provided a full valuation allowance against the deferred income tax assets, since it has a history of losses, which are all attributable to the U.S. and currently does not have enough positive evidence required under U.S. GAAP to reverse its valuation allowance. Management does not believe it is more likely than not that its deferred tax assets relating to the loss carryforwards and other temporary differences will be realized in the future. For the years ended December 31, 2013 and 2014, the valuation allowance increased by $6,104 and $6,912, respectively, resulting principally from increased operating loss carryforward.
	At December 31, 2014, the Company had U.S. federal and state net operating loss carryforwards of approximately $54,837 and $34,173, respectively, that can be carried forward and offset against future taxable income. These net operating loss carryforwards will begin to expire in 2029. Utilization of net operating losses may be subject to a substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986, and similar state provisions. The annual limitation may result in the expiration of net operating losses before utilization. The Company has not yet determined whether any changes in ownership have caused limitations.
	Significant judgment is required in evaluating the Company’s tax positions and in determining the Company’s provision for income taxes. In the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. As of December 31, 2014, the Company was not under audit in any tax jurisdiction. The U.S. statute of limitations will remain open to examination by the tax authorities until the utilization of net operating loss carryforwards. The Company accrues interest and penalties, if any, related to unrecognized tax benefits in income tax expense.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Stockholders' Equity	10	Stockholders’ Equity
	The Company had issued and outstanding Series A through E Redeemable Convertible Preferred Stock prior to the Acquisition Transaction. In connection with the Acquisition transaction, the Series A through E Redeemable Convertible Preferred Stock was converted to Common Stock. Accordingly, all shares and per share amounts have been retrospectively adjusted for all periods presented to reflect (i) the conversion of the Series A through E Redeemable Convertible Preferred Stock into Common Stock and (ii) the one for 25.00207 exchange of shares of Common Stock.
	Holders of Common Stock shall be entitled to receive dividends when and if declared by the Board of Directors. No dividends have been declared to date. In certain events, including the liquidation, dissolution or winding up of the Company, the remaining assets of the Company shall be distributed ratably among the holders of Common Stock.
	Holders of Common Stock are entitled to vote on all matters and are entitled to the number of votes equal to the number of common shares held.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	11	Stock-Based Compensation
	In connection with the Acquisition, Corindus exchanged options to purchase shares of its Common Stock for YIDI’s options to purchase shares of YIDI’s Common Stock (the “Replacement Plan Options”). The 2014 Stock Award Plan (the 2014 Plan) is the replacement plan for options previously awarded under the Corindus, Inc. 2006 Umbrella Option Plan and the Corindus, Inc. 2008 Stock Incentive Plan and is the plan under which all future Company options will be issued. The 2014 Stock Award Plan is limited to award issuances which in the aggregate cannot exceed 9,035,016 shares, all of which shares will be used for the issuance of the Company stock-based awards, including options to purchase common stock, restricted stock and restricted stock units. Replacement Plan Options are exercisable for up to ten years from the date of original vesting commencement date of the options.
	A summary of the activity under the Company’s stock option plans is as follows. Such information has been retrospectively adjusted to give effect to the exchange of stock options that occurred upon the Acquisition.
			Options			Weighted-		Weighted-		Aggregate
						Average		Average		Intrinsic
						Exercise		Remaining		Value
						Price		Contractual
								Term (Years)
	Outstanding at December 31, 2013			8,548,357		$	0.62		7	$	394
	Granted			882,070		$	0.77
	Cancelled			(752,410	)	$	0.6
	Outstanding at December 31, 2014			8,678,017		$	0.64		6.3	$	31,359
	Exercisable at December 31, 2014			6,377,398		$	0.6		5.56	$	23,299
	Vested and expected to vest at December 31, 2014			8,539,979		$	0.63		6.27	$	30,846
	Options available for grant at December 31, 2014			356,999
	Stock-based compensation expense was allocated based on the employees’ function as follows:
			Years Ended December 31,
			2013			2014
	Research and development		$	59		$	95
	Selling, general and administrative			270			282
			$	329		$	377
	The fair value of employee options is estimated on the date of each grant using the Black-Scholes Model. The weighted-average grant date fair value of options granted during the year ended December 31, 2013 and 2014 were $0.24 and $0.16, respectively. As of December 31, 2014, there was approximately $427 of unrecognized compensation cost related to non-vested stock-based compensation arrangements under the 2014 Plan. That cost is expected to be recognized over a weighted-average period of 2.29 years.
	At December 31, 2014, there were 14,242,395 shares of Common Stock reserved for the potential exercise of warrants (5,207,379) and stock options (9,035,016).

Warrants_to_Purchase_Common_St

Warrants to Purchase Common Stock	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Warrants to Purchase Common Stock	12	Warrants to Purchase Common Stock
	In connection with the Acquisition, the Company exchanged warrants to purchase 201,178 shares of Corindus, Inc. Series A, D and E Redeemable Convertible Preferred Stock at an average exercise price of $26.63 per share to warrants to purchase 5,029,865 shares of the Company’s Common Stock at the average exercise price of $1.07 per share.
	Prior to the Acquisition, the warrants were treated as liability instruments and were measured on a recurring basis at their fair value with inputs categorized as Level 3 in the fair value hierarchy. The resulting gain or loss on revaluation was recorded as other income (expense) in the consolidated statements of operations. The Company estimated the fair value of these warrants using the Black-Scholes Model based on the estimated market value of the underlying Redeemable Convertible Preferred Stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying Redeemable Convertible Preferred Stock.
	The Company revalued the warrants for the final time at the date of the Acquisition, which resulted in a charge of $2,421 for the year ended December 31, 2014. A roll forward of the warrant liability is as follows:
	Balance at December 31, 2012		$	2,981
	Revaluation of warrants			171
	Balance at December 31, 2013			3,152
	Issuance of warrants in connection with lending arrangement			230
	Revaluation of warrants			2,421
	Reclassification of warrant liability to stockholders’ equity			(5,803	)
	Balance at December 31, 2014		$	—
	The Company used the following assumptions for the valuation of its warrant liability:
			December 31, 2013				August 12, 2014
	Risk-free interest rate			1.18	%			1.025	%
	Dividend yield			0	%			0	%
	Expected volatility			80	%			50	%
	Expected term (years)			3.83				3.5
	The Company has following warrants outstanding at December 31, 2014:
	Exercise Price		Date of Expiration		Number of Warrants
	$1.06		October 11, 2017			4,728,191
	$0.76		May 31, 2017			124,160
	$1.41		June 11, 2024			355,028
						5,207,379

Commitments

Commitments	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments	13	Commitments
	The Company has an operating lease for approximately 26,400 square feet at its corporate headquarters and manufacturing plant in Waltham, Massachusetts, which expires in January 2018. The lease terms include escalating rent payments over the life of the lease and rent expense is recognized over the life of the lease on a straight-line basis. The difference between the amount expensed and actual rent payments are recorded as a deferred rent included within accrued expense in the consolidated balance sheets. In connection with the lease, the Company is required to maintain a security deposit with its landlord, which declines every six months during the lease until December 31, 2015, at which point the amount remains constant at $134. The total amount of the security deposit is approximately $267 at December 31, 2014, of which $89 is included in prepaid expenses and other current assets. The Company also leases copiers and vehicles under operating leases that expire at various points through 2018.
	Total rent expense was $584 and $577 for the fiscal years 2013 and 2014, respectively. At December 31, 2014, the Company’s future minimum lease payments are indicated below:
	Year ending December 31:		Total Lease Payments
	2015		$	577
	2016			590
	2017			598
	2018			59
	Total		$	1,824
	The Company is subject to potential claims from time to time in the ordinary course of business. At December 31, 2014, the Company is not subject to any significant asserted or unasserted claims.

Net_Loss_per_Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Net Loss per Share	14	Net Loss per Share
	Net loss per share for all periods presented is based on the equity structure of the legal acquirer, which assumes Common Stock is outstanding and is reflected on a retrospective basis for all periods presented of the conversion of Corindus, Inc.’s Preferred Stock and Common Stock into shares of the Company’s Common Stock. Basic net loss per share is computed by dividing net loss by the weighted average shares of common stock outstanding for each period. Diluted net loss per share is the same as basic net loss per share since the Company has net losses for each period presented. The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
			Years Ended December 31,
			2013		2014
	Options to purchase Common Stock			8,548,357		8,678,017
	Warrants to purchase Common Stock			4,852,351		5,207,379
	Total			13,400,708		13,885,396

Restructuring_Charge

Restructuring Charge	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring Charge	15	Restructuring Charge
	During 2014, the Company initiated reductions in workforce to control costs while the Company pursued new financing alternatives. During 2014, the Company recorded $175 in restructuring charges for severance and related costs, which were paid in 2014.

401k_Plan

401(k) Plan	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
401(k) Plan	16	401(k) Plan
	The Company has a tax-qualified employee savings and retirement 401(k) plan, covering all qualified employees. Participants may elect a salary deferral up to the statutorily prescribed annual limit for tax-deferred contributions. The Company has not made any matching contributions to date.

Immaterial_Correction_of_Error

Immaterial Correction of Errors	12 Months Ended
	Dec. 31, 2014
Accounting Changes and Error Corrections [Abstract]
Immaterial Correction of Errors	17	Immaterial Correction of Errors
	During 2014, the Company identified and recorded certain errors in previously issued 2013 consolidated financial statements and 2014 interim consolidated financial statements. The errors principally relate to inventory overhead costs which affected inventories, property and equipment, and cost of revenue amounts. The previously reported 2013 net loss in the amount of $14,691 was understated by $578. The errors during the second quarter and third quarter of 2014 were $51 and $31, respectively, and the correction of the error in the fourth quarter of 2014 was $536, principally affecting cost of revenue and gross loss. The Company concluded that the errors identified were not material to the 2013 consolidated financial statements and that correction of the errors in 2014 was not material to its 2014 consolidated financial statements.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events	18	Subsequent Events
	The Company has evaluated all events or transactions that occurred after December 31, 2014 through the date of filing of the Form 10-K. In the judgment of management, there were no material events that impacted the consolidated financial statements or disclosures.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation
	The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Corindus, Inc. and Corindus Security Corporation, which was created on December 21, 2012 to hold and invest the proceeds from issuance of equity. All intercompany transactions and balances have been eliminated in consolidation. The functional currency of both wholly-owned subsidiaries is the U.S. dollar and, therefore, the Company has not recorded any currency translation adjustments.
Reclassification	Reclassification
	Sales and marketing expenses of $5,676 in 2013 have been reclassified to selling, general and administrative expenses to conform to 2014 presentation.
Segment Information	Segment Information
	The Company operates in one business segment, which is the marketing, sales and development of robotic-assisted vascular interventions. Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions regarding resource allocation and assessing performance. To date, the chief operating decision maker has made such decisions and assessed performance at the company level, as one segment. The Company’s chief operating decision maker is the Chief Executive Officer.
	Revenues from domestic customers amounted to $896 in 2013 and approximately $2,200 in 2014. Revenues from international customers, primarily in Dubai and Israel, amounted to none in 2013 and approximately $1,000 in 2014.
Use of Estimates	Use of Estimates
	The process of preparing financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements. Such management estimates include those relating to revenue recognition, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards and warrants, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates.
Financial Instruments	Financial Instruments
	Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-level hierarchy is used to prioritize the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements), and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below:
	Level 1 – Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 – Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. If the asset or liability has a specified (contractual) term, a Level 2 input must be observable for substantially the full term of the asset or liability.
	Level 3 – Level 3 inputs are unobservable inputs for the asset or liability in which there is little, if any, market activity for the asset or liability at the measurement date.
	There were no assets and liabilities as of December 31, 2014 that are measured and recorded in the financial statements at fair value on a recurring basis. There were no transfers between Level 1, 2 or 3 assets or liabilities during the years ended December 31, 2013 or 2014. The following table shows the Company’s assets and liabilities as of December 31, 2013 that are measured and recorded in the financial statements at fair value on a recurring basis:
			December 31, 2013
			Quoted Prices in			Significant			Unobservable
			Active Markets for			Other			Inputs
			Identical			Observable Inputs
			Assets or Liabilities
			Level 1			Level 2			Level 3
	Assets
	Money market funds (a)		$	9,700		$	—		$	—
	Liabilities
	Warrant liability (b)		$	—		$	—		$	3,152
	(a)	The fair values of the Company’s money market funds, which are included in cash and cash equivalents, are based on quotes received from third-party banks.
	(b)	See Note 12 for a roll-forward of the warrant liability and a discussion of the valuation of this financial instrument.
	The Company’s financial instruments of deposits and notes receivable are carried at cost and approximate their fair values given the liquid nature of such items. The fair value of the Company’s long-term debt amounted to $8,748 at December 31, 2014, which was based on a discounted cash flow analysis, which included level 3 inputs.
Cash Equivalents	Cash Equivalents
	The Company considers highly liquid short-term investments, which consist of money market funds, with original maturity dates of three months or less at the date of purchase to be cash equivalents. From time to time, the Company’s cash balances may exceed federal deposit insurance limits.
Product Warranty and Allowance for Doubtful Accounts	Product Warranty and Allowance for Doubtful Accounts
	The Company’s allowance for doubtful accounts was $3 and none at December 31, 2013 and 2014, respectively. The Company’s accounts receivable consist primarily of amounts due from large, well-capitalized customers and while the Company reviews their creditworthiness, collectability is generally not an issue. The Company records an allowance for doubtful accounts, when necessary, based on the potential for minor collectability issues within the customer base. The amounts have not been material to date.
	Customers are permitted to return defective products under the Company’s standard product warranty program. For CorPath Systems, the Company’s standard one-year warranty provides for the repair of any product that malfunctions. Return and replacement can only occur if a material breach of the warranty remains uncured for 30 days. A roll-forward of the Company’s warranty liability is as follows:
	Balance at December 31, 2012		$	19
	Provision for warranty obligations			57
	Settlements			(47	)
	Balance at December 31, 2013			29
	Provisions for warranty obligations			96
	Settlements			(64	)
	Balance at December 31, 2014		$	61
Inventories	Inventories
	Inventories are valued at the lower of cost or market using the first-in, first-out (FIFO) method. The Company routinely monitors the recoverability of its inventory and records lower of cost or market reserves based on current selling prices and reserves for excess and obsolete inventory based on historical and forecasted usage, as required. Scrap and excess manufacturing costs are charged to cost of revenue as incurred and not capitalized as part of inventories.
Property and Equipment	Property and Equipment
	Property and equipment is carried at cost. Major items and betterments are capitalized; maintenance and repairs are charged to expense as incurred. The Company capitalizes certain costs incurred in connection with developing or obtaining internal-use software. Software costs that do not meet capitalization criteria are expensed as incurred. Demonstration equipment represents internally manufactured capital equipment that is used on-site at trade shows and at customer locations to demonstrate the CorPath System. Field equipment represents internally manufactured capital equipment placed at customer locations under a program that involves the placement of a system at the customer’s site and the customer’s agreement to purchase a minimum number of cassettes each month. At December 31, 2014, the Company had placed five field equipment units and one unit for a customer’s evaluation under such arrangements.
	Depreciation on the demonstration equipment is charged to selling, general and administrative and the deprecation on the field equipment is charged to cost of revenue. Depreciation is computed under the straight-line method over the estimated useful lives of the respective assets.
	Depreciation is provided over the following estimated asset lives:
	Machinery and equipment		5 years
	Computer equipment		3 years
	Office furniture and equipment		5 years
	Leasehold improvements		Shorter of life of lease or useful life
	Vendor tooling		3 years
	Software		4 years
	Demonstration equipment		3 years
	Field equipment		3 years
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	The Company’s long-lived assets principally consist of property and equipment. The Company continually monitors events and changes in circumstances that could indicate carrying amounts of long-lived assets may not be recoverable. An impairment loss is recognized when expected cash flows are less than an asset’s carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating performance and estimated future undiscounted cash flows of the underlying assets. The Company’s policy is to record an impairment loss when it is determined that the carrying amount of the asset may not be recoverable. No such impairment charges have been recognized.
Revenue Recognition	Revenue Recognition
	The CorPath System is a capital medical device used by hospitals and surgical centers to perform heart catheterizations. Use of the CorPath System requires a sterile, single-use cassette (the “CorPath Cassette”), which are sold separately, for each procedure. Products are sold to customers with no rights of return. The Company recognizes revenue on the sale of products when the following criteria are met:
		•		Persuasive evidence of an arrangement exists
		•		The price to the buyer is fixed or determinable
		•		Collectability is reasonably assured
		•		Risk of loss transfers and the product is delivered.
	In each arrangement, the Company is responsible for installation of the CorPath System and initial user training, which services are deemed essential to the functionality of the system. Therefore, the Company recognizes system revenue when the CorPath System is delivered and installed, and accepted by the end user customer.
	Each CorPath System is sold with a standard one year warranty, which provides that the CorPath System will function as intended and during that one year period, the Company will either replace the product or a portion thereof or provide the necessary repair service during the Company’s normal service hours. The Company accrues for the estimated costs of the warranty once the CorPath System revenue is recognized.
	The Company generally enters into multiple element arrangements, which include the sale of a CorPath System with an initial order of CorPath Cassettes, and may include either a basic service plan or a premium service plan. The basic service plan provides for an extended warranty period and the premium service plan provides for the extended warranty as well as component upgrades. Deliverables, which are accounted for as separate units of accounting under multiple-element arrangements include: (a) the CorPath System, including delivery installation and initial training, which are subject to customer acceptance and (b) the initial shipment of CorPath Cassettes to the customer, and may include either (c) a basic service plan or (d) a premium service plan.
	The Company recognizes revenue on multiple-element arrangements in accordance with Accounting Standards Update (“ASU”) 2009-13, Revenue Recognition (Topic 605): Multiple Deliverable Revenue Arrangements, based on the estimated selling price of each element. In accordance with ASU 2009-13, the Company uses vendor-specific objective evidence (“VSOE”), if available, to determine the selling price of each element. If VSOE is not available, the Company uses third-party evidence (“TPE”) to determine the selling price. If TPE is not available, the Company uses its best estimate to develop the estimated selling price (“BESP”). The Company uses BESP to determine the selling price of its systems as well as the basic and premium service plans. BESP is determined based on estimated costs plus a reasonable margin, and has generally been consistent with the price charged to the customer for such products and services. The determination of BESP also considers the price of the service plans charged to customers when such services are sold separately in subsequent transactions. The Company also uses BESP to determine the selling price of the initial order of cassettes, which considers the price at which it charges its customers when the cassettes are sold separately.
	Revenue related to basic service plans is recognized on a straight-line basis over the life of the service contract. Revenue related to premium service plans is recognized over the life of the service contract, with consideration given to the expected timing of costs to be incurred related to the delivery of component upgrades. Revenues from accessories are recorded upon delivery and services provided by the Company outside of a basic or premium service contract are recognized as the services are provided.
	There are no performance, cancellation, termination, and refund-type provisions under the Company’s multiple element arrangements.
	On January 21, 2011, the Company entered into a distributor agreement with Philips Medical Systems Nederland, B.V. (“Philips”) appointing Philips to be the sole worldwide distributor for the promotion and sale of the Company’s CorPath System. Under the agreement, Philips sold the equipment directly to the end user and the Company was responsible for installation and initial training. Revenue was recognized on a net basis based on the amount billed to Philips and upon acceptance of the system by the end-user customer. At December 31, 2013, Philips owed the Company $125, for systems shipped under the distribution agreement. At December 31, 2014, there were no amounts outstanding from Philips. This agreement with Philips expired on August 7, 2014.
	The Company also sells CorPath Cassettes under a CorPath Utilization Program (“CUP”), which is a multi-year arrangement that involves the placement of a CorPath System at a customer’s site free of charge and the customer agrees to purchase a minimum number of CorPath Cassettes each month at a premium over the regular price. The Company records revenue upon shipment of the cassettes based on the selling price of the CorPath Cassettes. The system is capitalized as field equipment in property and equipment and is depreciated on a straight line basis through cost of revenue over the estimated useful life of the system, which generally approximates the length of the CUP program contract, which is typically 36 months. Revenues under this program have not been significant to date.
	The Company also uses a One-Stent program to demonstrate its confidence in the CorPath System’s ability to help accurately measure anatomy and precisely place only one stent per lesion. The Company provides eligible customers registered under the program a $1 credit against future CorPath Cassette purchases for a qualifying CorPath percutaneous coronary intervention (“PCI”) procedure which uses more than one stent per lesion. The estimated cost of honoring the potential obligation under the stent program is recorded as a reduction of revenue at the time of shipment. These costs have not been significant to date.
	The Company records shipping and handling costs as a selling expense in the period incurred, and records payments from customers for shipping costs as a reduction of selling expenses. Such amounts have not been material in the periods presented. The Company recorded medical device excise tax in the amount of $29 in 2013 and $40 in 2014, which is included in selling, general and administrative expenses.
Research and Development	Research and Development
	Costs for research and development are expensed as incurred. Research and development expense consists primarily of salaries, salary-related expenses and costs of contractors and materials.
Income Taxes	Income Taxes
	The Company accounts for income taxes using the liability method, whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to amounts that are realizable.
	The Company accounts for uncertain tax positions using a “more-likely-than-not” threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The Company evaluates these tax positions on an annual basis. The Company also accrues for potential interest and penalties related to unrecognized tax benefits in income tax expense.
	The Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.
Stock-Based Compensation	Stock-Based Compensation
	The Company recognizes compensation costs resulting from the issuance of stock-based awards to employees as an expense in the consolidated statements of operations over the requisite service period based on a measurement of fair value for each stock award. The Company recognizes compensation costs resulting from the issuance of stock-based awards to non-employees as an expense in the consolidated statements of operations over the service period based on a measurement of fair value for each stock award at each performance date and period end.
	Prior to the completion of the reverse acquisition, the fair value of the common stock was determined by the Board of Directors after considering a broad range of factors, including the results obtained from an independent third-party valuation, the illiquid nature of an investment in the Company’s Common Stock, the Company’s historical financial performance and financial position, the Company’s future prospects and opportunity for liquidity events, and recent sale and offer prices of Common and Preferred Stock in private transactions negotiated at arm’s length. Subsequent to the completion of the reverse acquisition, the fair value of the Common Stock was obtained from quoted market prices on the OTCQB as provided by OTC Market Groups, Inc.
	The following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes-Merton option-pricing model (“Black Scholes Model”):
			Years Ended December 31,
			2013			2014
	Risk-free interest rate			0.72% to 1.43	%		1.89% to 2.01	%
	Expected term in years			5.75 to 6.25			6.25
	Expected volatility			80	%		50	%
	Expected dividend yield			0	%		0	%
	The risk-free interest rate assumption is based upon observed U.S. government security interest rates with a term that is consistent with the expected term of the Company’s employee stock options. The expected term is based on the average of the vesting period and contractual term of the Company’s options given the lack of historical data available. The Company does not pay a dividend, and is not expected to pay a dividend in the foreseeable future.
	Due to a lack of a public market for the Company’s Common Stock for an extended period of time, the Company utilized comparable public companies’ volatility rates as a proxy of its expected volatility for purposes of the Black-Scholes Model. Stock-based compensation expense is recorded net of estimated forfeitures and is adjusted periodically for actual forfeitures. The Company uses historical data to estimate forfeiture rates. For the year-ended December 31, 2013 and 2014, forfeitures were estimated to be 4.9% and 6.0%, respectively.
Warrant Liability	Warrant Liability
	The Company reviews the terms of warrants issued in connection with the applicable accounting guidance and classifies warrants as a long-term liability on the consolidated balance sheets if the warrant may conditionally obligate the Company to transfer assets, including repurchase of the Company’s capital stock, at some point in the future. Warrants to purchase shares of redeemable convertible preferred stock met these criteria and therefore required liability-classification. The Company classifies warrants within stockholders’ equity on the consolidated balance sheets if the warrants are considered to be indexed to the Company’s own capital stock, and otherwise would be recorded in stockholders’ equity.
	Liability-classified warrants are subject to re-measurement at each balance sheet date, and any change in fair value is recognized as a component of other income (expense) in the consolidated statements of operations. The Company estimates the fair value of these warrants at issuance and each balance sheet date thereafter using the Black-Scholes Model as described in the stock-based compensation section above, based on the estimated market value of the underlying Redeemable Convertible Preferred Stock at the valuation measurement date, the remaining contractual term of the warrant, risk-free interest rates, expected dividends and expected volatility of the price of the underlying redeemable convertible preferred stock. The fair value of the Redeemable Convertible Preferred Stock was determined by the Board of Directors after considering a broad range of factors, including the results obtained from an independent third-party valuation, the illiquid nature of an investment in the Company’s Redeemable Convertible Preferred Stock, the Company’s historical financial performance and financial position, the Company’s future prospects and opportunity for liquidity events, and recent sale and offer prices of Common and Preferred Stock in private transactions negotiated at arm’s length.
	The Company had warrants outstanding to purchase shares of Series A, D and E Redeemable Convertible Preferred Stock, which converted into warrants to purchase shares of Common Stock at the date of the Acquisition. Prior to the Acquisition, the warrant instruments required mark-to-market accounting which was recorded in the statements of operations based on their fair values determined using the Black-Scholes Model and the fair value of underlying Preferred Stock. The warrant instruments were re-valued for the last time at the date of the Acquisition and reclassified into stockholders’ equity in 2014.
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers
	The Company had one customer, Philips, who accounted for approximately 71% and 11% of its revenues in 2013 and 2014, respectively. Philips also accounted for approximately 78% and 0% of its accounts receivables at December 31, 2013 and 2014, respectively. The Company had no other customers that accounted for greater than 10% of its revenues or greater than 10% of its accounts receivable as of December 31, 2013.
	The Company had the following other customers that accounted for greater than 10% of its revenues in 2014:
	Customer		Percent of Revenues
	A			27	%
	B			11	%
	C			12	%
	D			10	%
	Additionally, Customer C accounted for 27% of the Company’s accounts receivable balance at December 31, 2014. The Company also had one other customer that accounted for 25% of its accounts receivable balance at December 31, 2014, but did not exceed 10% of its revenues in 2014.
	The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.
Related-Party Transactions	Related-Party Transactions
	On January 21, 2011, the Company entered into a distributor agreement with Philips appointing Philips to be the sole distributor for the promotion and sale of the Company’s CorPath System. The agreement was terminated on August 7, 2014. The Company continues to sell CorPath Systems through Philips on a sale by sale basis under a non-exclusive arrangement under mutually agreeable terms, which may include a continued level of discounted pricing, until such time the Company either executes a new distribution arrangement with Philips or the Company no longer does business with Philips.
	For the years ended December 31, 2013 and 2014, the Company recorded revenues of $630 and $315, respectively, from shipments to Philips under the distribution agreement. At December 31, 2013 and 2014, Philips owed the Company $125 and $0, respectively, resulting from selling activity under the agreement.
	In the fourth quarter of 2014, the Company participated in the formation of a not-for-profit, which was established to generate awareness of the health risks linked to the use of fluoroscopy in hospital catheterization. The Company’s Chief Executive Office and one of its senior executives represent two of the three voting members of the board of directors of the entity. As a result, under the voting model used for the consolidation of related parties, which are controlled by a company, the Company has consolidated the financial statements of the entity, which have no assets or liabilities on its balance sheet at December 31, 2014 and expenses of approximately $18.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued ASU No. 2014-09 – Revenue from Contracts with Customers (Topic 606). ASU 2014-09 supersedes most of the existing guidance on revenue recognition in Accounting Standards Codification (“ASC”) Topic 605, Revenue Recognition. The core principle of the revenue model is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In applying the revenue model to contracts within its scope, an entity will need to (i) identify the contract(s) with a customer (ii) identify the performance obligations in the contract (iii) determine the transaction price (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU No. 2014-09 is effective for public entities for annual and interim periods beginning after December 15, 2016. The ASU allows for either full retrospective adoption, where the standard is applied to all of the periods presented, or modified retrospective adoption, where the standard is applied only to the most current period presented in the financial statements. The Company is currently assessing the impact of this standard to its consolidated financial statements.
	In January 2015, the FASB issued Financial Accounting Standards Update - Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items. Subtopic 225-20, Income Statement—Extraordinary and Unusual Items, previously required that an entity separately classify, present, and disclose extraordinary events and transactions. This update is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015 and may be applied prospectively or retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company is currently assessing the impact of this standard to its consolidated financial statements.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table shows the Company’s assets and liabilities as of December 31, 2013 that are measured and recorded in the financial statements at fair value on a recurring basis:
			December 31, 2013
			Quoted Prices in			Significant			Unobservable
			Active Markets for			Other			Inputs
			Identical			Observable Inputs
			Assets or Liabilities
			Level 1			Level 2			Level 3
	Assets
	Money market funds (a)		$	9,700		$	—		$	—
	Liabilities
	Warrant liability (b)		$	—		$	—		$	3,152
	(a)	The fair values of the Company’s money market funds, which are included in cash and cash equivalents, are based on quotes received from third-party banks.
	(b)	See Note 12 for a roll-forward of the warrant liability and a discussion of the valuation of this financial instrument.
Roll-forward of warranty liability	A roll-forward of the Company’s warranty liability is as follows:
	Balance at December 31, 2012		$	19
	Provision for warranty obligations			57
	Settlements			(47	)
	Balance at December 31, 2013			29
	Provisions for warranty obligations			96
	Settlements			(64	)
	Balance at December 31, 2014		$	61
Property and Equipment, Estimated Useful Lives	Depreciation is provided over the following estimated asset lives:
	Machinery and equipment		5 years
	Computer equipment		3 years
	Office furniture and equipment		5 years
	Leasehold improvements		Shorter of life of lease or useful life
	Vendor tooling		3 years
	Software		4 years
	Demonstration equipment		3 years
	Field equipment		3 years
Assumptions Used to Estimate Fair Value of Stock Options Granted Using Black-Scholes Option Pricing Model	The following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes-Merton option-pricing model (“Black Scholes Model”):
			Years Ended December 31,
			2013			2014
	Risk-free interest rate			0.72% to 1.43	%		1.89% to 2.01	%
	Expected term in years			5.75 to 6.25			6.25
	Expected volatility			80	%		50	%
	Expected dividend yield			0	%		0	%
Schedule of concentration of customers	The Company had the following other customers that accounted for greater than 10% of its revenues in 2014:
	Customer		Percent of Revenues
	A			27	%
	B			11	%
	C			12	%
	D			10	%

Reverse_Acquisition_Tables

Reverse Acquisition (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Business Acquisitions	Prior to the divestiture of YIDI’s former business, the Company performed an allocation of the purchase price for YIDI based on estimated fair value of the acquired assets and liabilities prior to the disposition of the remaining business of YIDI:
	Purchase price-assumption of note payable to former officer	$	249
	Allocation of purchase price:
	Intangible assets acquired	$	262
	Accrued expenses assumed		(13	)
	Net assets acquired	$	249

Inventories_Tables

Inventories (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventories	The Company’s inventories consist of the following:
		December 31,
		2013		2014
	Raw materials	$	634	$	861
	Work in progress		—		198
	Finished goods		1,830		460
		$	2,464	$	1,519

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment consist of the following:
		December 31,
		2013			2014
	Machinery and equipment	$	298		$	334
	Computer equipment		273			273
	Office furniture and equipment		353			355
	Leasehold improvements		63			67
	Vendor tooling		671			711
	Software		450			490
	Demonstration equipment		669			633
	Field equipment		205			588
			2,982			3,451
	Less accumulated depreciation and amortization		(1,545	)		(2,167	)
	Property and equipment, net	$	1,437		$	1,284

Accrued_Expenses_Tables

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following:
		December 31,
		2013		2014
	Payroll and benefits	$	493	$	185
	Professional and consultant fees		242		496
	Product development costs		117		62
	Commissions		107		85
	Warranty		29		61
	Other		273		248
		$	1,261	$	1,137

LongTerm_Debt_Tables

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Assumption for the Valuation of Warrants Issued	The Company used the following assumptions for the valuation of its warrants issued on the following dates:
		June 11, 2014			December 31, 2014
	Risk-free interest rate		2.5	%		2.17	%
	Dividend yield		0	%		0	%
	Expected volatility		50	%		50	%
	Expected term (years)		10			9.44
Schedule of Future Principal Payments Under Borrowing Arrangement	Future principal payments under the borrowing arrangement as of December 31, 2014 are as follows:
	Year ending December 31:
	2015	$	2,022
	2016		4,378
	2017		3,600
		$	10,000

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Reconciliation of Effective Income Tax rate	The Company’s effective income tax rate differs from the statutory federal income tax rate as follows:
		Years Ended December 31,
		2013			2014
	Statutory U.S. federal rate		34	%		34	%
	State income tax		4.7			1.7
	Permanent items		0.6			(3.8	)
	Change in taxing status in Massachusetts to a manufacturer		—			(4.9	)
	Other		(0.8	)		(0.7	)
	Federal R&D credits		2			1.2
	State R&D and other credits		0.5			0.7
	Change in valuation allowance		(41.0	)		(28.2	)
	Total expense (benefit)		—	%		—	%
Schedule of Deferred Income Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and the related valuation allowance were as follows, in thousands:
		December 31,
		2013			2014
	Deferred income tax assets:
	Operating loss carryforwards	$	12,299		$	20,178
	Start-up expenditures		3,316			2,807
	Property and equipment		99			46
	Intangible assets		3,059			2,589
	Stock-based compensation expense		666			738
	Research and development credit carryforwards		878			1,216
	Accrued expenses and other		652			307
	Total deferred income tax assets		20,969			27,881
	Valuation allowance		(20,969	)		(27,881	)
	Net deferred income tax assets	$	—		$	—

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of the Activity Under the Company's Stock Option Plans	A summary of the activity under the Company’s stock option plans is as follows. Such information has been retrospectively adjusted to give effect to the exchange of stock options that occurred upon the Acquisition.
		Options			Weighted-		Weighted-		Aggregate
					Average		Average		Intrinsic
					Exercise		Remaining		Value
					Price		Contractual
							Term (Years)
	Outstanding at December 31, 2013		8,548,357		$	0.62		7	$	394
	Granted		882,070		$	0.77
	Cancelled		(752,410	)	$	0.6
	Outstanding at December 31, 2014		8,678,017		$	0.64		6.3	$	31,359
	Exercisable at December 31, 2014		6,377,398		$	0.6		5.56	$	23,299
	Vested and expected to vest at December 31, 2014		8,539,979		$	0.63		6.27	$	30,846
	Options available for grant at December 31, 2014		356,999
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense was allocated based on the employees’ function as follows:
		Years Ended December 31,
		2013			2014
	Research and development	$	59		$	95
	Selling, general and administrative		270			282
		$	329		$	377

Warrants_to_Purchase_Common_St1

Warrants to Purchase Common Stock (Tables)	12 Months Ended
	Dec. 31, 2014
Text Block [Abstract]
Rollforward of Warrant Liability	A roll forward of the warrant liability is as follows:
	Balance at December 31, 2012	$	2,981
	Revaluation of warrants		171
	Balance at December 31, 2013		3,152
	Issuance of warrants in connection with lending arrangement		230
	Revaluation of warrants		2,421
	Reclassification of warrant liability to stockholders’ equity		(5,803	)
	Balance at December 31, 2014	$	—
Schedule of Assumptions in Revaluation of Outstanding Warrants	The Company used the following assumptions for the valuation of its warrant liability:
		December 31, 2013				August 12, 2014
	Risk-free interest rate		1.18	%			1.025	%
	Dividend yield		0	%			0	%
	Expected volatility		80	%			50	%
	Expected term (years)		3.83				3.5
Schedule of Warrants Outstanding	The Company has following warrants outstanding at December 31, 2014:
	Exercise Price	Date of Expiration		Number of Warrants
	$1.06	October 11, 2017			4,728,191
	$0.76	May 31, 2017			124,160
	$1.41	June 11, 2024			355,028
					5,207,379

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Lease Payments	At December 31, 2014, the Company’s future minimum lease payments are indicated below:
	Year ending December 31:	Total Lease Payments
	2015	$	577
	2016		590
	2017		598
	2018		59
	Total	$	1,824

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Securities Excluded from Computation of Net Loss per Share	The following common stock equivalents were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
		Years Ended December 31,
		2013		2014
	Options to purchase Common Stock		8,548,357		8,678,017
	Warrants to purchase Common Stock		4,852,351		5,207,379
	Total		13,400,708		13,885,396

Nature_of_Operations_Additiona

Nature of Operations - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Aug. 12, 2014	Dec. 31, 2014	Sep. 16, 2014	Dec. 31, 2013	Dec. 31, 2012
Description of acquisition agreement		(i) all outstanding shares of common stock of Corindus, Inc., $0.01 par value per share, were exchanged for shares of Company common stock, $0.0001 par value per share, and (ii) all outstanding options and warrants to purchase shares of common stock of Corindus, Inc. were exchanged for or replaced with options and warrants to acquire shares of common stock of the Company
Common stock, par value		$0.00		$0.00
Description of exchange ratio		The exchange ratio was one for 25.00207 shares
Exchange ratio of common stock		25.00207
Transfer of former business in satisfaction of promissory note	$249
Issuance of common stock in connection with private placement of common stock, net of offering costs		25,487
Accumulated deficit		84,877		60,336
Net borrowings outstanding		9,111
Contractual obligation due in 2015		2,000
Cash and cash equivalents		28,526		9,845	25,536
Working capital		26,231
Debt covenant maturity description		Throughout 2015
Private Placement [Member]
Share price (in dollars per share)	$2		$2.50
Issuance of common stock in connection with private placement of common stock, net of offering costs, shares			10,666,570
Gross proceeds from private placement			26,666
Issuance of common stock in connection with private placement of common stock, net of offering costs			$25,487
Reverse acquisition - YIDI [Member]
Shares of common stock issued in conversion of redeemable convertible preferred stock	2,811,499
Common stock, par value	$0.01
Exchange ratio of common stock	25.00207

Significant_Accounting_Policie3

Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Significant Accounting Policies [Line Items]
Sales and marketing expenses		$5,676,000
Transfer of between level 1 and level 2 assets	0	0
Transfer of between level 1 and level 2 liabilities	0	0
Fair value of the Company's long-term debt	8,748,000
Allowance for doubtful accounts	0	3,000
Company's standard product warranty period	1 year
Warranty description	Return and replacement can only occur if a material breach of the warranty remains uncured for 30 days
Impairment charges of long-lived assets	0
Warranty period of systems sold	1 year
Due from related party	0	125,000
Estimated useful lives	36 months
Credit provided to eligible customers	1,000
Medical device excise tax	40,000	29,000
Estimated forfeitures rates	6.00%	4.90%
Revenue from related party	315,000	630,000
Related party transaction expense	18,000
Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Number of customers	1
Revenues [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage	11.00%	71.00%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage	0.00%	78.00%
Minimum [Member] | Revenues [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage		10.00%
Minimum [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage	10.00%	10.00%
Maximum [Member] | Revenues [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage	10.00%
Fair Value, Measurements, Recurring [Member]
Significant Accounting Policies [Line Items]
Assets fair value on recurring basis	0	0
Liabilities fair value on recurring basis	0	0
Field Equipment [Member]
Significant Accounting Policies [Line Items]
Number of field equipments placed	5
Customer Evaluation [Member]
Significant Accounting Policies [Line Items]
Number of field equipments placed	1
Domestic Customers [Member]
Significant Accounting Policies [Line Items]
Revenues from domestic customers	2,200,000	896,000
International Customers [Member]
Significant Accounting Policies [Line Items]
Revenues from domestic customers	$1,000,000	$0
Customer C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage	27.00%
Other Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration percentage	25.00%

Significant_Accounting_Policie4

Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 1 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Money market funds	$9,700
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant liability	$3,152

Significant_Accounting_Policie5

Significant Accounting Policies - Roll-forward of Warranty Liability (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]
Beginning balance, Product warrant liability	$29	$19
Provision for warranty obligation	96	57
Settlements	-64	-47
Ending balance, Product warrant liability	$61	$29

Significant_Accounting_Policie6

Significant Accounting Policies - Property and Equipment, Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Estimated useful lives	36 months
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Shorter of life of lease or useful life
Vendor Tooling [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	4 years
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Field Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years

Significant_Accounting_Policie7

Significant Accounting Policies - Assumptions Used to Estimate Fair Value of Stock Options Granted Using Black-Scholes-Merton Option Pricing Model (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurement [Line Items]
Expected term in years	6 years 3 months
Expected volatility	50.00%	80.00%
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Fair Value Measurement [Line Items]
Risk-free interest rate	1.89%	0.72%
Expected term in years		5 years 9 months
Maximum [Member]
Fair Value Measurement [Line Items]
Risk-free interest rate	2.01%	1.43%
Expected term in years		6 years 3 months

Significant_Accounting_Policie8

Significant Accounting Policies - Schedule of Concentration of Customers (Detail) (Revenues [Member])	12 Months Ended
	Dec. 31, 2014
Customer A [Member]
Concentration Risk [Line Items]
Concentration percentage	27.00%
Customer B [Member]
Concentration Risk [Line Items]
Concentration percentage	11.00%
Customer C [Member]
Concentration Risk [Line Items]
Concentration percentage	12.00%
Customer D [Member]
Concentration Risk [Line Items]
Concentration percentage	10.00%

Reverse_Acquisition_Additional

Reverse Acquisition - Additional Information (Detail) (USD $)	12 Months Ended	0 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Aug. 12, 2014	Dec. 31, 2013
Business Acquisition [Line Items]
Common stock, par value	$0.00		$0.00
Exchange of common stock shares	94,216,587
Exchange ratio of common shares	25.00207
Acquisition Percentage	80.00%
Acquisition cost	$1,100
Reverse acquisition - YIDI [Member]
Business Acquisition [Line Items]
Promissory note		$249
Common stock, par value		$0.01
Exchange ratio of common shares		25.00207
Corindus Inc. [Member]
Business Acquisition [Line Items]
Common stock, par value	$0.01

Reverse_Acquisition_Schedule_o

Reverse Acquisition - Schedule of Business Acquisitions (Detail) (Reverse acquisition - YIDI [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Reverse acquisition - YIDI [Member]
Business Acquisition [Line Items]
Purchase price-assumption of note payable to former officer	$249
Allocation of purchase price:
Intangible assets acquired	262
Accrued expenses assumed	-13
Net assets acquired	$249

Inventories_Additional_Informa

Inventories - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Inventory Disclosure [Abstract]
Write down of inventories	$341

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$861	$634
Work in progress	198
Finished goods	460	1,830
Inventories, net	$1,519	$2,464

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Property plant and equipment depreciation expense	$622	$607

Property_and_Equipment_Summary

Property and Equipment - Summary of Property and Equipment, Net (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$3,451	$2,982
Less accumulated depreciation and amortization	-2,167	-1,545
Property and equipment, net	1,284	1,437
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	334	298
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	273	273
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	355	353
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	67	63
Vendor Tooling [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	711	671
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	490	450
Demonstration Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	633	669
Field Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, Gross	$588	$205

Notes_Receivable_Additional_In

Notes Receivable - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
	Jun. 14, 2010	Dec. 31, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]
Issuance of notes receivable due from stockholder	$145,000
Notes receivable outstanding		136,000	145,000
Notes Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Impairment cost for notes receivable		$0	$0

Accrued_Expenses_Schedule_of_A

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Payroll and benefits	$185	$493
Professional and consultant fees	496	242
Product development costs	62	117
Commissions	85	107
Warranty	61	29
Other	248	273
Accrued expenses	$1,137	$1,261

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)	0 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 11, 2014	Dec. 31, 2014	Jun. 11, 2014
Line of Credit Facility [Line Items]
Debt, net of discounts		9,111
Loan and Security Agreement
Line of Credit Facility [Line Items]
Available borrowing under Loan and Security Agreement	10,000		10,000
Amount of each separate note		5,000
Debt, unamortized discount		889
Debt, net of discounts		9,111
Loan and Security Agreement | Initial Promissory Note
Line of Credit Facility [Line Items]
Amount of each separate note	5,000		5,000
Note issuance date	11-Jun-14
Frequency of debt payments		Monthly
Term of debt payments	27 months
Date of first required payment	1-Jul-15
Interest rate, minimum	11.25%
Interest rate, description of maximum		11.25% plus the Wall Street Journal Prime Rate, less 3.25%
Spread on variable rate	-3.25%
Additional interest payment	125,000
Due date of additional interest payment	1-Oct-17
Number of shares callable by warrants outstanding	177,514		177,514
Warrant strike price (in dollars per share)	$1.41		$1.41
Fair value of the warrant issued	230		230
Loan and Security Agreement | Second Promissory Note
Line of Credit Facility [Line Items]
Amount of each separate note		5,000
Frequency of debt payments		Monthly
Term of debt payments		27 months
Date of first required payment		1-Jul-15
Interest rate, minimum		9.95%
Interest rate, description of maximum		9.95% plus the Wall Street Journal Prime Rate, less 3.25%
Additional interest payment		125,000
Due date of additional interest payment		1-Oct-17
Number of shares callable by warrants outstanding		177,514
Warrant strike price (in dollars per share)		1.41
Fair value of the warrant issued		619

LongTerm_Debt_Assumption_for_t

Long-Term Debt - Assumption for the Valuation of Warrants Issued (Detail)	0 Months Ended		12 Months Ended
	Aug. 12, 2014	Jun. 11, 2014	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Dividend yield			0.00%	0.00%
Expected volatility			50.00%	80.00%
Expected term (years)			6 years 3 months
Warrant [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	1.03%	2.50%	2.17%	1.18%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected volatility	50.00%	50.00%	50.00%	80.00%
Expected term (years)	3 years 6 months	10 years	9 years 5 months 9 days	3 years 9 months 29 days

LongTerm_Debt_Schedule_of_Futu

Long-Term Debt - Schedule of Future Principal Payments Under Borrowing Arrangement (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]
2015	$2,022
2016	4,378
2017	3,600
Long term debt	$10,000

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Effective Income Tax rate (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Statutory U.S. federal rate	34.00%	34.00%
State income tax	1.70%	4.70%
Permanent items	-3.80%	0.60%
Change in taxing status in Massachusetts to a manufacturer	-4.90%
Other	-0.70%	-0.80%
Federal R&D credits	1.20%	2.00%
State R&D and other credits	0.70%	0.50%
Change in valuation allowance	-28.20%	-41.00%
Total expense (benefit)	0.00%	0.00%

Income_Taxes_Schedule_of_Defer

Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Deferred income tax assets:
Operating loss carryforwards	$20,178	$12,299
Start-up expenditures	2,807	3,316
Property and equipment	46	99
Intangible assets	2,589	3,059
Stock-based compensation expense	738	666
Research and development credit carryforwards	1,216	878
Accrued expenses and other	307	652
Total deferred income tax assets	27,881	20,969
Valuation allowance	-27,881	-20,969
Net deferred income tax assets	$0	$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Income Tax Examination [Line Items]
Change in valuation allowance	$6,912	$6,104
State Jurisdiction [Member]
Income Tax Examination [Line Items]
Net operating loss carryforwards		34,173
US Federal [Member]
Income Tax Examination [Line Items]
Net operating loss carryforwards	$54,837

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Equity [Abstract]
Exchange ratio of common stock	25.00207
Dividends declared	$0

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of options granted	$0.16	$0.24
Unrecognized compensation costs related to non-vested stock-based compensation	$427
Costs expected to be recognized over weighted-average period	2 years 3 months 15 days
Shares reserved for exercises	14,242,395
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for exercises	9,035,016
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for exercises	5,207,379
The 2014 Stock Award Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under plan	9,035,016
Shares exercisable period	P10Y

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of the Activity Under the Company's Stock Option Plans (Detail) (Stock Options [Member], USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding, beginning balance	8,548,357
Options, granted	882,070
Options, cancelled	-752,410
Options outstanding, ending balance	8,678,017	8,548,357
Options, exercisable	6,377,398
Options, vested and expected to vest	8,539,979
Options available for grant	356,999
Weighted-Average Exercise Price Per Share, Options outstanding, beginning balance	$0.62
Weighted-Average Exercise Price Per Share, granted	$0.77
Weighted- Average Exercise Price Per Share, cancelled	$0.60
Weighted- Average Exercise Price Per Share, Options outstanding, ending balance	$0.64	$0.62
Weighted- Average Exercise Price Per Share, Options exercisable	$0.60
Weighted-Average Exercise Price Per Share, Options vested and expected to vest	$0.63
Weighted-Average Remaining Contractual Term in Years, Options outstanding	6 years 3 months 18 days	7 years
Weighted-Average Remaining Contractual Term in Years, Options exercisable	5 years 6 months 22 days
Weighted-Average Remaining Contractual Term in Years, Options vested and expected to vest	6 years 3 months 7 days
Aggregate Intrinsic Value, Options outstanding	$31,359	$394
Aggregate Intrinsic Value, Options exercisable	23,299
Aggregate Intrinsic Value, Options vested and expected to vest	$30,846

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$377	$329
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	95	59
Selling General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation expense	$282	$270

Warrants_to_Purchase_Common_St2

Warrants to Purchase Common Stock - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Number of shares to be converted by warrant pre-exchange	201,178
Average exercise price	$26.63
Number of shares to be converted by warrant post-exchange	5,029,865
Common stock average price per share	$1.07
Revaluation of warrants	$2,421	$171

Warrants_to_Purchase_Common_St3

Warrants to Purchase Common Stock - Rollforward of Warrant Liability (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Beginning balance	$3,152
Revaluation of warrants	-2,421	-171
Reclassification of warrant liability to stockholders' equity	-5,803
Ending balance		3,152
Warrant [Member]
Class of Warrant or Right [Line Items]
Beginning balance	3,152	2,981
Issuance of warrants in connection with lending arrangement	230
Revaluation of warrants	2,421	171
Reclassification of warrant liability to stockholders' equity	-5,803
Ending balance		$3,152

Warrants_to_Purchase_Common_St4

Warrants to Purchase Common Stock - Schedule of Assumptions in Revaluation of Outstanding Warrants (Detail)	0 Months Ended		12 Months Ended
	Aug. 12, 2014	Jun. 11, 2014	Dec. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Dividend yield			0.00%	0.00%
Expected volatility			50.00%	80.00%
Expected term (years)			6 years 3 months
Warrant [Member]
Class of Warrant or Right [Line Items]
Risk-free interest rate	1.03%	2.50%	2.17%	1.18%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Expected volatility	50.00%	50.00%	50.00%	80.00%
Expected term (years)	3 years 6 months	10 years	9 years 5 months 9 days	3 years 9 months 29 days

Warrants_to_Purchase_Common_St5

Warrants to Purchase Common Stock - Schedule of Warrants Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Number of Warrants	5,207,379
Expired on October 11, 2017 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$1.06
Date of Expiration	11-Oct-17
Number of Warrants	4,728,191
Expired on May 31, 2017 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$0.76
Date of Expiration	31-May-17
Number of Warrants	124,160
Expired on June11, 2014 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$1.41
Date of Expiration	11-Jun-24
Number of Warrants	355,028

Commitments_Additional_Informa

Commitments - Additional Information (Detail) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
	sqft
Commitments And Contingencies Disclosure [Line Items]
Office and manufacturing lease (square footage)	26,400
Operating lease expiration date	31-Jan-18
Security deposit	$267
Amount of prepaid expenses and other assets	89
Operating leases expiration year	2018
Rent expense	577	584
Scenario, Forecast [Member]
Commitments And Contingencies Disclosure [Line Items]
Security deposit			$134

Commitments_Schedule_of_Future

Commitments - Schedule of Future Minimum Lease Payments (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Commitments and Contingencies Disclosure [Abstract]
2015	$577
2016	590
2017	598
2018	59
Total	$1,824

Net_Loss_per_Share_Schedule_of

Net Loss per Share - Schedule of Securities Excluded from Computation of Net Loss per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive securities	13,885,396	13,400,708
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive securities	8,678,017	8,548,357
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of anti-dilutive securities	5,207,379	4,852,351

Restructuring_Charge_Additiona

Restructuring Charge - Additional Information (Detail) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Restructuring and Related Activities [Abstract]
Restructuring charges - severance and related costs	$175

Immaterial_Correction_of_Error1

Immaterial Correction of Errors - Additional Information (Detail) (USD $)	3 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013
Accounting Changes and Error Corrections [Abstract]
Net loss				($24,541)	($14,691)
Error corrections during the period	$536	$31	$51		$578